Notice of Liability

to the U.S. Food & Drug Administration (FDA) in Anticipation of the Emergency Use Approval of the Experimental Gene Therapy Injections for Children From 5 Years Old

The well-established requirement to obtain informed consent prior to administering medical procedures on people is not vitiated by mandates or social regulations.

"We for Humanity" is an initiative founded by a group of Holocaust survivors and their descendants. From historical experience we warn: It is the end of any pluralistic democratic society when medicine, science, justice, culture and media submit to the dictates of the political executive and the greed for profit.

A crime is premeditated when it is committed with foreknowledge & specific intent prior to the commission of the crime. We hereby publicly call your attention to the following facts (not exhaustive) that demand an immediate halt to the global vaccination program on children and adults alike.

The so-called vaccinations are an ongoing experiment, so everyone injected is a test subject. **Therefore, the Nuremberg Code applies** and all those who are culpable will be prosecuted to the fullest extent of the law.

As you know, the injections are not really vaccinations, but gene therapies. Attached are three slides from the May 18, 2021 event "Genetic Vaccine Development for Infectious Diseases". The Summit took place five months into the global "vaccination" campaign where presenters found a place to "*share unpublished data on gene-based vaccine"* and to "*cover clinical trial updates for pregnant women",* to name two topics.

Also, the EU Directive 2009/120/EC using global standards reads under fig. 2.1: "*Gene therapy medicinal products shall not include vaccines against infectious diseases*."

If not for mislabeling the experimental gene therapy as "vaccination", a vast majority would neither subject themselves nor their children to these experimental gene therapies. By this mislabeling alone, you have deprived people of a crucial basis for informed consent. As a reminder, read the last sentence of the first principle of the Nuremberg Code: **everyone involved is personally liable**.

Furthermore, by mislabeling, you violated 42 U.S. Code § 262 - Regulation of Biological Products. This code states under section (b) that "*No person shall mislabel or misbrand a package or container of a biological product or alter a label or marking on the package or container of the biological product so as to falsify the label or marking*." Subjecting people to highly experimental gene therapies under the name of Covid 19 Vaccine, is nothing short of malfeasance, the **willful violation of federal law**, and the intentional disregard of the safety of others which is a shameful dereliction of your duty.

Your false assurances that "*people can be assured of FDA's unwavering commitment to public health through our comprehensive and rigorous evaluation of the data submitted*" are patently untrue.

You are on notice that Pfizer has a long history of drug marketing fraud. A chain of Freedom of Information requests has revealed that the agencies questioned could not produce patient-level data from Pfizer, thereby negating their specious safety claims. By granting approval absent a thorough review of the patient-level data the FDA has therefore breached its duty of care, let alone applied any such "*rigorous evaluation.*"

This is likewise untrue that – here quoted again – "*for each vaccine, FDA has evaluated and analyzed the safety and effectiveness data".* But, how could you whilst still running the Phase 3 of a medical experiment, at this very moment? European Medicines Agency (EMA) using the same standards states in its Guidelines under fig. 4.3.1 regarding vector therapy, that after treatment testing should continue for at least 5 years. Instead, the ongoing experiment was extended to include infants less than one year, after it was already forced upon their parents and grandparents.

The claim that the experimental gene therapy imposes less risk than COVID-19 is more disinformation from the FDA with consequences for which you are criminally liable. Even with under 1% reporting rate of the adverse effects (see Lazarus report, P. 6) it is obvious that the experimental injections cause considerably more harm than the disease it targets. A review of the German adverse event report on the one hand and the Covid statistics on the other shows that more children and adolescents (evaluation of reported cases only) have been affected by adverse effects following "vaccination" than by Sars-Cov-2. Myo-/pericarditis are being reported "*with the highest reporting rate in male adolescents aged 12 to 17 years, followed by young men aged 18 to 29 years*."

A close study of the Nuremberg Code reveals that all ten principles have been violated so far.

People may forgive a mistake. But, not the deliberate murder of their children. You are on notice.

Do the right thing for humanity. Do the right thing for the children.

We for Humanity
trust-in-humanity@pm.me
https://we-for-humanity.org

###END###

References

https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=OJ:L:2009:242:FULL&from=EN

https://www.law.cornell.edu/uscode/text/42/262

https://www.justice.gov/opa/pr/justice-department-announces-largest-health-care-fraud-settlement-its-history

https://doctors4covidethics.org/regulation-or-racket-uk-drug-regulator-never-inspected-the-pfizer-vaccine-study-data/

https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-follow-patients-administered-gene-therapy-medicinal-products_en.pdf.

https://digital.ahrq.gov/sites/default/files/docs/publication/r18hs017045-lazarus-final-report-2011.pdf

https://we-for-humanity.org/notice-of-liability-vaccination/

https://media.tghn.org/medialibrary/2011/04/BMJ_No_7070_Volume_313_The_Nuremberg_Code.pdf

Welcome to the Inaugural Genetic Vaccine Development for Infectious Diseases Summit

The 3-day case study-led program will bring together a wealth of knowledge into the complexities of the new and emerging field of gene-based vaccines, bringing together both pioneering academics and non-profit institutions, and leading biotech and pharma. Expect to hear updates on long-term clinical efficacy and safety, immune responses, novel delivery methods, and genetic platforms.

Attend this event to:

Understand how the optimization of lipid nanoparticles allows for efficient and safe delivery of mRNA

Hear **Moderna** speak on the use of their mRNA technology platform for the development of mRNA-based vaccines, and a case study on mRNA-1273, one of the first approved COVID-19 vaccines

Learn the critical steps in mRNA vaccine development that allowed for the 'lightspeed' deployment of a SARS-CoV-2 vaccine

From pre-clinical studies to large-scale manufacture, **BioNTech** will be sharing how they went about developing the first COVID-19 vaccine, as well as sharing pre-clinical data on wider infectious disease programs

Optimizing next-generation vaccine development and lessons learned from COVID-19

Take part in an interactive panel discussion with **Pfizer** to learn how new vaccine technologies can stave off future outbreaks, and how the future of vaccine development has been changed by COVID-19

Discover the latest updates in DNA-based vaccines against infectious diseases

Hear **INOVIO** speak on efficacy in animal challenge models, thermo-stability of DNA vaccines, and clinical immunogenicity and safety profiling of INO-4800 in the race to be the first approved DNA vaccine for human use

Clinical and operational challenges of COVID-19 vaccine development and future opportunities

Understand how defining clinical trial endpoints for a new pathogen with limited pre-existing evidence can be overcome, why we need correlates of protection, and how to establish vaccine efficacy when placebo-controlled trials become more difficult

Welcome to the Inaugural Genetic Vaccine Development for Infectious Diseases Summit

Overcome the Translational Challenges of Developing mRNA, DNA & Engineered Viral Vector-Based Vaccines

The **Genetic Vaccine Development for Infectious Diseases Summit** will focus on overcoming the translational and clinical challenges of developing genetic vaccines targeting infectious diseases.

The agenda will cover clinical trial updates for pregnant women on COVID-19 candidates and long-term correlates of protection, plus our expert speakers will share *unpublished data* on gene-based vaccines for a wide range of infectious diseases, including **Influenza**, **Lassa fever**, **Ebola**, **MERS**, **HIV**, **Zika**, and **COVID-19**.

With a focus on mRNA, DNA, and engineered viral vector-based vaccines, this niche 3-day agenda has been specifically designed to help industry experts to:

Progress your own expertise and forge powerful collaborations with leading biotech, pharma, academics & NPOs

Overcome immunogenicity challenges to design safe and efficacious vaccine formulations

Define clinically meaningful endpoints to successfully develop and safely deliver optimal doses for public use

Form Powerful Collaborations with Pioneering Biopharma

The digital **Genetic Vaccine Development for Infectious Diseases Summit** is not only the first, but the *only* industry-dedicated meeting that brings you the most up-to-date clinical and commercial developments utilizing next-generation vaccine technologies for infectious diseases.

Join 100+ experts online from companies such as BioNTech, Pfizer, Moderna, AstraZeneca, CureVac and more to discuss new genetic-based vaccine platforms, preclinical and clinical case studies, optimized delivery methods, and the future of vaccine R&D to usher in a new era of vaccinology.

Pre-Conference Symposium: SARS-CoV-2

By May, millions of doses of SARS-CoV-2 vaccines will have been administered. We have curated a tailored and focused program specifically on the SARS-CoV-2 pathogen to bring you updates on safety and effectiveness, correlates of protection, duration of long-term immunity, and use in potentially at-risk population groups such as pregnant women, children, and allergy sufferers

Tuesday, May 18 (AM)

9:00 Update on Clinical Trials Involving Pregnant Women with COVID-19 Vaccines

9:30 Controlled Human Infection Models to Further Validate the Efficacy of COVID-19 Vaccines

10:00 Development of an mRNA-based COVID-19 Vaccine at 'lightspeed': From Pre-Clinical Studies to Large-scale Manufacture

10:30 Moderna's COVID-19 Vaccine: A Summary of Available Clinical Data

11:30 Clinical and Operational Challenges of COVID-19 Vaccine Development and Future Opportunities

Tuesday, May 18 (PM)

12:00 INO-4800 – A DNA based Vaccine Against COVID-19

12:30 CVnCov: CureVac's mRNA-based Vaccine Candidate Against COVID-19

2:00 Immunogenicity of Chimpanzee Adenovirus Vector Vaccines Expressing SARS-CoV2 Spike and Nucleocapsid

2:30 Development of AAVCOVID: A Single Dose AAV-based Vaccine for COVID-19

3:00 A Framework to Analyse the Pandemic Potential of Pathogens: COVID-19 and Future Directions